Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)

被引：73

作者：

Aparicio, T. ^{[1
,2
]}

Lavau-Denes, S. ^{[3
]}

Phelip, J. M. ^{[4
]}

Maillard, E. ^{[5
]}

Jouve, J. L. ^{[6
]}

Gargot, D. ^{[7
]}

Gasmi, M. ^{[8
]}

Locher, C. ^{[9
]}

Adhoute, X. ^{[10
]}

Michel, P. ^{[11
]}

Khemissa, F. ^{[12
]}

Lecomte, T. ^{[13
]}

Provencal, J. ^{[14
]}

Breysacher, G. ^{[15
]}

Legoux, J. L. ^{[16
]}

Lepere, C. ^{[17
]}

Charneau, J. ^{[18
]}

Cretin, J. ^{[19
]}

Chone, L. ^{[20
]}

Azzedine, A. ^{[21
]}

Bouche, O. ^{[22
]}

Sobhani, I. ^{[23
]}

Bedenne, L. ^{[5
,6
]}

Mitry, E. ^{[24
,25
]}

机构：

[1] CHU Avicenne, AP HP, Dept Gastroenterol, Bobigny, France

[2] Univ Paris 13, Sorbonne Paris Cite, F-93000 Bobigny, France

[3] CHU Dupuytren, Dept Oncol, Limoges, France

[4] CHU St Etienne, Hop Nord, Dept Gastroenterol, St Priest En Jarez, France

[5] Federat Francophone Cancerol Digest, FFCD Data Ctr, Dijon, France

[6] CHU Bocage, Dept Gastroenterol, Dijon, France

[7] CH Blois, Dept Gastroenterol, Blois, France

[8] CHU Hop Nord, Dept Gastroenterol, Marseille, France

[9] CH Meaux, Dept Gastroenterol, Meaux, France

[10] CHU Haut Leveque, Dept Gastroenterol, Pessac, France

[11] CHU Charles Nicolle, Dept Gastroenterol, Rouen, France

[12] CH St Jean, Dept Gastroenterol, Perpignan, France

[13] CHU Trousseau, Dept Gastroenterol, Tours, France

[14] CH Chambery, Dept Oncol, Chambery, France

[15] CH Pasteur, Dept Gastroenterol, Colmar, France

[16] CH Source, Dept Gastroenterol, Orleans, France

[17] CHU Georges Pompidou, AP HP, Dept Digest Oncol, Paris, France

[18] CH Duchenne, Dept Gastroenterol, Boulogne, France

[19] Clin Bonnefon, Dept Oncol, Ales, France

[20] CHU Nancy, Dept Gastroenterol, Vandoeuvre Les Nancy, France

[21] CH Avignon, Dept Gastroenterol, Avignon, France

[22] CHU Robert Debre, Dept Gastroenterol, Reims, France

[23] CHU Henri Mondor, AP HP, Dept Gastroenterol, F-94010 Creteil, France

[24] Inst Curie, Dept Oncol, St Cloud, France

[25] Univ Versailles St Quentin, St Quentin en Yvelines, France

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷 / 01期

关键词：

elderly; colorectal cancer; chemotherapy; geriatric oncology; HIGH-DOSE LEUCOVORIN; OPEN-LABEL; COMBINATION CHEMOTHERAPY; CONTINUOUS-INFUSION; OLDER PATIENTS; FLUOROURACIL; OXALIPLATIN; FOLFIRI; BEVACIZUMAB; 5-FLUOROURACIL;

D O I：

10.1093/annonc/mdv491

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients. However, data from a geriatric tailored randomized trial about tolerance to and the efficacy of doublet chemotherapy (CT) with irinotecan in the elderly are lacking. The benefit of first-line CT intensification remains an issue in elderly patients. Elderly patients (75+) with previously untreated mCRC were randomly assigned in a 2 x 2 factorial design (four arms) to receive 5-FU (5-fluorouracil)-based CT, either alone (FU: LV5FU2 or simplified LV5FU2) or in combination with irinotecan [IRI: LV5FU2-irinotecan or simplified LV5FU2-irinotecan (FOLFIRI)]. The CLASSIC arm was defined as LV5FU2 or LV5FU2-irinotecan and the SIMPLIFIED arm as simplified LV5FU2 or FOLFIRI. The primary end point was progression-free survival (PFS). Secondary end points were overall survival (OS), safety and objective response rate (ORR). From June 2003 to May 2010, 71 patients were randomly assigned to LV5FU2, 71 to simplified LV5FU2, 70 to LV5FU2-irinotecan and 70 to FOLFIRI. The median age was 80 years (range 75-92 years). No significant difference was observed for the median PFS: FU 5.2 months versus IRI 7.3 months, hazard ratio (HR) = 0.84 (0.66-1.07), P = 0.15 and CLASSIC 6.5 months versus SIMPLIFIED 6.0 months, HR = 0.85 (0.67-1.09), P = 0.19. The ORR was superior in IRI (P = 0.0003): FU 21.1% versus IRI 41.7% and in CLASSIC (P = 0.04): CLASSIC 37.1% versus SIMPLIFIED 25.6%. Median OS was 14.2 months in FU versus 13.3 months in IRI, HR = 0.96 (0.75-1.24) and 15.2 months in CLASSIC versus 11.4 months in SIMPLIFIED, HR = 0.71 (0.55-0.92). More patients presented grade 3-4 toxicities in IRI (52.2% versus 76.3%). In this elderly population, adding irinotecan to an infusional 5-FU-based CT did not significantly increase either PFS or OS. Classic LV5FU2 was associated with an improved OS compared with simplified LV5FU2. NCT00303771.

引用

页码：121 / 127

页数：7

共 26 条

[1] CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer [J].

André, T ;

Louvet, C ;

Maindrault-Goebel, F ;

Couteau, C ;

Mabro, M ;

Lotz, JP ;

Gilles-Amar, V ;

Krulik, M ;

Carola, E ;

Izrael, V ;

de Gramont, A .

EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) :1343-1347

[2] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly [J].

Aparicio, T ;

Desramé, J ;

Lecomte, T ;

Mitry, E ;

Belloc, J ;

Etienney, I ;

Montembault, S ;

Vayre, L ;

Locher, C ;

Ezenfis, J ;

Artru, P ;

Mabro, M ;

Dominguez, S .

BRITISH JOURNAL OF CANCER, 2003, 89 (08) :1439-1444

[3] Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients [J].

Aparicio, Thomas ;

Jouve, Jean-Louis ;

Teillet, Laurent ;

Gargot, Dany ;

Subtil, Fabien ;

Le Brun-Ly, Valerie ;

Cretin, Jacques ;

Locher, Christophe ;

Bouche, Olivier ;

Breysacher, Gilles ;

Charneau, Jacky ;

Seitz, Jean-Francois ;

Gasmi, Mohamed ;

Stefani, Laetitia ;

Ramdani, Mohamed ;

Lecomte, Thierry ;

Mitry, Emmanuel .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) :1464-1470

[4] Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial [J].

Cunningham, David ;

Lang, Istvan ;

Marcuello, Eugenio ;

Lorusso, Vito ;

Ocvirk, Janja ;

Shin, Dong Bok ;

Jonker, Derek ;

Osborne, Stuart ;

Andre, Niko ;

Waterkamp, Daniel ;

Saunders, Mark P. .

LANCET ONCOLOGY, 2013, 14 (11) :1077-1085

[5] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[6] Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study [J].

deGramont, A ;

Basset, JF ;

Milan, C ;

Rougier, P ;

Bouche, O ;

Etienne, PL ;

Morvan, F ;

Louvet, C ;

Guillot, C ;

Francois, E ;

Bedenne, L .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :808-815

[7] Elderly patients with colorectal cancer: Treatment modalities and survival in France. National data from the ThInDiT cohort study [J].

Doat, S. ;

Thiebaut, A. ;

Samson, S. ;

Ricordeau, P. ;

Guillemot, D. ;

Mitry, E. .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) :1276-1283

[8] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[9] Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial [J].

Ducreux, Michel ;

Malka, David ;

Mendiboure, Jean ;

Etienne, Pierre-Luc ;

Texereau, Patrick ;

Auby, Dominique ;

Rougier, Philippe ;

Gasmi, Mohamed ;

Castaing, Marine ;

Abbas, Moncef ;

Michel, Pierre ;

Gargot, Dany ;

Azzedine, Ahmed ;

Lombard-Bohas, Catherine ;

Geoffroy, Patrick ;

Denis, Bernard ;

Pignon, Jean-Pierre ;

Bedenne, Laurent ;

Bouche, Olivier .

LANCET ONCOLOGY, 2011, 12 (11) :1032-1044

[10] Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer:: Combined analysis of 2,691 patients in randomized controlled trials [J].

Folprecht, Gunnar ;

Seymour, Matthew T. ;

Saltz, Leonard ;

Douillard, Jean-Yves ;

Hecker, Hartmut ;

Stephens, Richard J. ;

Maughan, Timothy S. ;

Van Cutsem, Eric ;

Rougier, Philippe ;

Mitry, Emmanuel ;

Schubert, Ute ;

Koehne, Claus-Henning .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1443-1451

← 1 2 3 →